Research use only · EU-warehoused · COA on every batch · HPLC ≥99% · Shipment 2–5 days
Log in Register
Home/ Catalogue/ Encapsulated Compounds/ Larazotide Capsules
In stock
Larazotide Capsules

Larazotide Capsules

Lyophilised · ≥99% (HPLC) ·

Quantity Volume discounts auto-applied
Custom quantity
1

Supplied lyophilised. Reconstitution typically uses bacteriostatic water.

Independently third-party tested · COA on every batch · 48h EU dispatch
[01]

Overview

Larazotide (AT-1001) is a synthetic octapeptide tight-junction regulator that antagonises zonulin signalling at the intestinal epithelium, reducing paracellular permeability in in vitro and ex vivo gut-barrier models. CAS 258818-34-7; sequence H-Gly-Gly-Val-Leu-Val-Gln-Pro-Gly-OH; molecular formula C32H55N9O10; molecular weight 725.8 g/mol. Supplied encapsulated at research grade. For laboratory research use only; not for human or veterinary use.

Most peptides studied in the lab are designed to travel — to enter the bloodstream and act at distant tissues. Larazotide (also written larazotide acetate, AT-1001) is the opposite: an eight-residue peptide engineered to stay exactly where it lands. It works locally at the surface of the intestinal epithelium, where it has become one of the most-studied experimental tools for probing the integrity of the gut barrier.

A tight-junction regulator, not a systemic drug. The space between adjacent epithelial cells is sealed by tight junctions — protein complexes that decide what crosses the barrier and what is held back. Larazotide is investigated as a zonulin-pathway antagonist that opposes the disassembly of these junctions, and the zonulin axis it targets has been mapped as a central regulator of barrier function across chronic inflammatory states (Mohammadi-Kordkhayli et al., 2025). Because it is not appreciably absorbed, research models treat it as a compound that exerts its effects at the luminal interface rather than throughout the body (Damianos et al., 2026).

What the research explores. Across cell-culture and animal systems, Larazotide has been investigated along several converging lines:

  • Intestinal barrier & permeability models — examined as a tight-junction stabiliser in studies of barrier disruption and restoration in coeliac-disease paradigms (Damianos et al., 2026; D'heedene et al., 2024).
  • Epithelial-injury & protection assays — explored for mucosal-barrier protection against anoxia/reoxygenation injury and for sustained-release delivery in colitis models (Kim et al., 2025; Yu et al., 2025).
  • Receptor-pathway & inflammatory signalling — studied as a PAR2 antagonist in keratinocyte barrier-disruption assays and in viral-antigen clearance research (Glinka & MacGregor, 2025; Yonker et al., 2025).

The activity described here is drawn from in-vitro and animal studies; it characterises biological behaviour in experimental models and does not establish efficacy or safety in humans. Full citations are listed under the Scientific References tab.

Physicochemical profile. CAS No. 258818-34-7 · Molecular formula C32H55N9O10 · Molecular weight 725.84 g/mol · Sequence Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (8 aa) · Appearance: White lyophilized powder · Solubility: Soluble in water.

Specification & quality. Each bottle contains 60 HPMC (vegan) capsules, each providing 500mcg of Larazotide at ≥99% (HPLC). Encapsulated — no reconstitution required. Every batch is independently third-party tested, and a Certificate of Analysis (COA) is available. Store at -20°C, protect from light and moisture; shelf life 24 months from the manufacture date. EU warehoused.

This product is intended for laboratory research use only (RUO). It is not a drug, food, cosmetic, or dietary supplement, and is not for human or veterinary use, ingestion, or diagnostic application. Handling is restricted to qualified research professionals operating in an appropriately equipped laboratory.

Supplied for in-vitro laboratory research use only (RUO). Not a drug, food or supplement; not for human or veterinary use.

[04]

Quality & COA

Certificate of Analysis
Lot-specific COA with every order

Certificate of Analysis — lot-specific COA ships with every order and is available on request.

Each lot is tested by an independent third-party laboratory for identity (mass spectrometry) and purity (HPLC). The Certificate of Analysis for your specific batch ships with the order and is available on request — no house data, no exceptions.

HPLC purity
≥99% (HPLC)
Method
HPLC + MS
Endotoxin
Reported
[02]

Data Sheet

CAS number258818-34-7
Molecular formulaC32H55N9O10
Molecular weight725.84
SequenceGly-Gly-Val-Leu-Val-Gln-Pro-Gly (8 aa)
Purity≥99% (HPLC)
Physical formWhite lyophilized powder
Quantity60 capsules
SolubilitySoluble in water
StorageStore at -20°C, protect from light and moisture
ReconstitutionEncapsulated — no reconstitution required.
Shelf life24 months from manufacture date
Dose per capsule500mcg
Capsule materialHPMC (Vegan)
OriginEU · Slovakia
ClassificationResearch use only
[03]

Scientific References

01 Damianos JA, Bledsoe A, Camilleri M, Murray JA Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration. Gut. 2026;75(4):826-838. PMID: 40579122. doi:10.1136/gutjnl-2025-335373. PubMed 02 Kubala K, Pietrucha T, Goldyn M, Grabinska M, Halik P, Jusiak J Integrated Role of Microbial, Fungal, and Plant-Derived Interventions in the Management of Celiac Disease: A Narrative Review. Cureus. 2026;18(1):e102471. PMID: 41769533. doi:10.7759/cureus.102471. PubMed 03 Dipasquale V, Romano C New Therapeutic Challenges in Pediatric Gastroenterology: A Narrative Review. Healthcare (Basel, Switzerland). 2025;13(8). PMID: 40281872. doi:10.3390/healthcare13080923. PubMed 04 Girbal-González M, Pérez-Cano FJ Is There a Future Without Gluten Restrictions for Celiac Patients? Update on Current Treatments. Nutrients. 2025;17(18). PMID: 41010485. doi:10.3390/nu17182960. PubMed 05 Mohammadi-Kordkhayli M, Mousavi MJ, Camara-Lemarroy CR, Noorbakhsh F, Saboor-Yaraghi AA Elucidating the Significance of Zonulin in the Pathogenesis of Chronic Inflammatory Disorders: Emphasis on Intestinal Barrier Function and Tight Junction Regulation. Current medicinal chemistry. 2025;32(30):6547-6562. PMID: 39252622. doi:10.2174/0109298673335863240829060545. PubMed 06 D'heedene M, Vanuytsel T, Wauters L Celiac disease: Hope for new treatments beyond a gluten-free diet. Clinical nutrition (Edinburgh, Scotland). 2024;43(6):1240-1249. PMID: 38648685. doi:10.1016/j.clnu.2024.04.014. PubMed 07 Wehby GL Birthweight and Academic Achievement Through Adolescence. Academic pediatrics. 2026;26(3):103228. PMID: 41679541. doi:10.1016/j.acap.2026.103228. PubMed 08 Huang YC, Chiang Chiau JS, Cheng ML, Lee HC, Chan WT, Chang SW et al. Preventive effects of Larazotide acetate (AT-1001) on non-alcoholic fatty liver diseases (NAFLD) in a mouse model. Pediatrics and neonatology. 2026;67(1):84-88. PMID: 40562584. doi:10.1016/j.pedneo.2025.01.016. PubMed 09 Yamamoto K, Tanaka F, Nishida Y, Maruyama H, Ominami M, Nadatani Y et al. Potassium-Competitive Acid Blocker Increases Ileal Permeability and Exacerbates Ileal Inflammation under Stress Conditions in a Mouse Model of Eosinophilic Enteritis. Digestion. 2026;:1-18. PMID: 42008374. doi:10.1159/000552062. PubMed 10 Shu Y, Shang Z, Pengmei Z, Zhang L, Truhlar DG New Framework for Multi-Electronic-State Dynamics and Its Validation for Photoisomerization of 1,3-Cyclohexadiene. Journal of chemical theory and computation. 2026;22(9):4276-4287. PMID: 42017512. doi:10.1021/acs.jctc.6c00338. PubMed 11 Yu F, Chen Y, Ouyang S, Tong B, Jiang Z, Wang J et al. Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment. Journal of controlled release : official journal of the Controlled Release Society. 2025;387:114205. PMID: 40915363. doi:10.1016/j.jconrel.2025.114205. PubMed 12 Yonker LM, Kane AS, Swank Z, Papadakis L, Kenyon V, Han S et al. Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide. Science translational medicine. 2025;17(809):eadu4284. PMID: 40737433. doi:10.1126/scitranslmed.adu4284. PubMed 13 Glinka DM, MacGregor GG The PAR2 Antagonist Larazotide Can Mitigate Acute Histamine-Stimulated Epithelial Barrier Disruption in Keratinocytes: A Potential Adjunct Treatment for Atopic Dermatitis. JID innovations : skin science from molecules to population health. 2025;5(4):100369. PMID: 40330848. doi:10.1016/j.xjidi.2025.100369. PubMed 14 Kim J, Madan JP, Laumas S, Krishnan BR, Jin Y Larazotide Acetate Protects the Intestinal Mucosal Barrier from Anoxia/Reoxygenation Injury via Various Cellular Mechanisms. Biomedicines. 2025;13(10). PMID: 41153766. doi:10.3390/biomedicines13102483. PubMed 15 Wang Y, Huang Y, Liu X, Kang C, Wu W Rapid detection of drug abuse via tear analysis using surface enhanced Raman spectroscopy and machine learning. Scientific reports. 2025;15(1):1108. PMID: 39774298. doi:10.1038/s41598-025-85451-y. PubMed

References are illustrative of the research literature surrounding this compound. All claims relate to in-vitro and animal models only.

[05]

FAQ

Larazotide (larazotide acetate, AT-1001) is a synthetic eight-amino-acid peptide investigated as a tight-junction regulator and zonulin-pathway antagonist that acts locally at the intestinal epithelium. It is a key experimental tool in gut-barrier and intestinal-permeability research. Condor Research supplies it strictly as a Research Use Only reference compound for in vitro and animal studies, not as a medicine, supplement or product for human or veterinary use.

Larazotide is an eight-residue peptide studied specifically as a tight-junction regulator that stays at the luminal surface and opposes zonulin-driven barrier opening. BPC-157 is a different pentadecapeptide investigated more broadly for tissue-repair and angiogenic endpoints across multiple tissue models. They belong to different mechanistic classes and address distinct research questions, and both are supplied only as research-use-only reference compounds.

KPV is a short tripeptide fragment studied chiefly for anti-inflammatory signalling within epithelial and immune models, whereas Larazotide is studied as a structural barrier modulator acting on tight-junction assembly via the zonulin pathway. One probes inflammatory pathways, the other probes barrier integrity — complementary but mechanistically separate research questions. Both are offered exclusively for laboratory research use, not for human or veterinary use.

No. Larazotide is a gut-restricted, eight-residue barrier-modulating peptide investigated in intestinal-permeability models, while Epitalon is a four-residue pineal-derived peptide studied for telomerase and ageing-related endpoints. They share the peptide class but nothing of mechanism or research focus. Both are supplied solely as Research Use Only reference compounds.

Yes. Condor Research supplies Larazotide strictly as a Research Use Only reference compound to professionals and institutions, not as a medicine, supplement or product for human or veterinary use. Buyers are responsible for confirming import legality in their own country. Questions: info@condorresearch.com.

The capsule is simply a pre-weighed, encapsulated solid format that makes a fixed quantity of reference compound easy to store, inventory and handle in the laboratory. Each HPMC (vegan) capsule contains an accurately measured amount of material with no reconstitution required. The capsule format is a handling convenience for research and does not imply or permit any form of consumption. For laboratory research use only. Not for human or veterinary use.

No. The compound is already encapsulated as a solid powder, so no reconstitution is required for handling or storage. Researchers preparing experimental solutions follow their own validated protocols; Larazotide is described as water-soluble. This is a laboratory reference material supplied for research use only and not for human or veterinary use.

Each bottle contains 60 HPMC (vegan) capsules, with 500mcg of Larazotide per capsule at ≥99% HPLC purity. Every batch is independently third-party tested. The per-capsule quantity refers to the mass of reference compound for laboratory measurement only and is not a dose for human or veterinary use.

Larazotide has CAS No. 258818-34-7, molecular formula C32H55N9O10 and a molecular weight of 725.84 g/mol, with the sequence Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (8 aa). It presents as a white lyophilized powder that is soluble in water. These specifications are provided for research characterisation purposes only.

Yes. Every Larazotide batch is tested by an independent third-party laboratory by HPLC for identity and purity (≥99%), and each lot ships with a lot-specific Certificate of Analysis. To request the COA for your batch, contact info@condorresearch.com. The COA documents analytical quality for research use only.

Store at -20°C, protected from light and moisture, to preserve compound integrity over the stated 24-month shelf life from the manufacture date. The product is EU warehoused and shipped to support stability. It is supplied for laboratory research use only and is not for human or veterinary use, ingestion, or diagnostic application.

[06]

Reviews

Leave a review
Earn 250 points for a verified review (account required).
4.7
86 verified reviews
5
78%
4
16%
3
3%
2
1%
1
1%
Apr 2026
Reproducible across batches

Third order with Condor. Batch-to-batch variation is minimal, which matters for our longitudinal work. The mono-labelled vials are easy to track.

Dr. R. Costa · Academic lab · PT Verified purchase
Mar 2026
Exactly what research needs

No marketing fluff — just characterised material with paperwork. The data sheet and CAS matched our records precisely.

J. Meijer · Biotech R&D · NL Verified purchase
Mar 2026
High purity, clear labelling

Lyophilised cake was uniform and dissolved fully. Would appreciate a digital COA portal, but the PDF on request worked fine.

Dr. A. Bianchi · University · IT Verified purchase
Feb 2026
Trustworthy supplier

Identity by MS confirmed in our facility. Communication around storage and handling was precise and professional.

K. Wójcik · Research group · PL Verified purchase

Related compounds